REGN Share Price Performance
US$732.87
71.87 (10.87%)
10.7% undervalued intrinsic discount
US$821.12
Fair Value
Price US$732.87
AnalystConsensusTarget US$821.12
Vestra US$873.54
AnalystHighTarget US$1,009.20
Fair ValueUS$873.78
Share Pricen/a
Regeneron Pharmaceuticals, Inc. Stock Price
- 4 Narratives written by author
- 2 Comments on narratives written by author
- 178 Fair Values set on narratives written by author
REGN Community Narratives
AN
Fair Value US$873.78 16.1% undervalued intrinsic discount
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
2users have liked this narrative
2users have commented on this narrative
80users have followed this narrative
VE
Fair Value US$873.54 16.1% undervalued intrinsic discount
Regeneron Pharmaceuticals (REGN): The Defensive Titan of Biotechnology
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$1.01k 27.4% undervalued intrinsic discount
Dupixent And EYLEA Will Seize Expanding Global Markets
1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Regeneron Pharmaceuticals (REGN): The Defensive Titan of Biotechnology
Regeneron Pharmaceuticals (REGN) is demonstrating significant resilience as a defensive anchor in the biotech sector, closing at $744.12 USD as of March 18, 2026. While the stock faced a 1.97% intraday decline today amidst a broader market pullback, it continues to trade near the upper end of its 52-week range ($476 – $821).Read more
88
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
Key Takeaways Expanding pipeline, new indications, and emerging market access position the company for sustained revenue growth and increased long-term earnings. Ongoing R&D investment and advanced manufacturing provide cost advantages and margin protection amid shifts toward breakthrough technologies and personalized medicine.Read more
720
users have viewed this narrative2users have liked this narrative
2users have commented on this narrative
80users have followed this narrative
AN
US$873.78
16.1% undervalued intrinsic discount
Fair Value
Revenue
9.2% p.a.
Profit Margin
32.28%
Future PE
16.75x
Price in 2029
US$1.07k
US Healthcare Reforms And Biosimilars Will Erode Margins
Key Takeaways Reliance on a few key products and increasing biosimilar competition threaten revenue growth and earnings stability as healthcare reforms pressure pricing power. Rising R&D expenses and demographic headwinds may limit the long-term growth potential and sustainability of current revenue streams.Read more
145
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$730
0.4% overvalued intrinsic discount
Fair Value
Revenue
5.55% p.a.
Profit Margin
29.72%
Future PE
16.83x
Price in 2029
US$892.56
Dupixent And EYLEA Will Seize Expanding Global Markets
Key Takeaways Regeneron's best-in-class therapies, strong product adoption, and innovative pipeline position it for rapid market share gains and expanded, diversified long-term growth. Strategic investments in manufacturing and advanced biologics platforms enable operational efficiency, robust supply, and capitalize on rising global demand for precision medicines.Read more
164
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$1.01k
27.4% undervalued intrinsic discount
Fair Value
Revenue
13.15% p.a.
Profit Margin
34.82%
Future PE
15.44x
Price in 2029
US$1.23k
Trending Discussion
Recently Updated Narratives
VE
Regeneron Pharmaceuticals (REGN): The Defensive Titan of Biotechnology
Fair Value: US$873.54 16.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks
Fair Value: US$873.78 16.1% undervalued intrinsic discount
80 followersusers have followed this narrative
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks
Fair Value: US$730 0.4% overvalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Regeneron Pharmaceuticals, Inc. Key Details
About REGN
- Founded
- 1988
- Employees
- 15410
- CEO
- WebsiteView website
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.
